New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on August 13, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jacob Van Naarden, the Executive Vice President and President of Lilly Oncology, has made a significant investment by purchasing 1,000 shares of Eli Lilly & Co stock, valued at $647,360.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Neutral.
Eli Lilly & Co’s overall stock score is driven by strong financial performance and positive earnings call outcomes, indicating robust growth prospects. However, technical analysis reveals bearish trends, and the valuation suggests the stock is overvalued, which tempers the overall score.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: -16.86%
Average Trading Volume: 4,245,097
Technical Sentiment Signal: Hold
Current Market Cap: $605.2B